Revvity, Inc.

Valuation Analysis

About the Company

Revvity, Inc. en bref

Revvity, Inc. (RVTY) is currently trading at 87,16 € with a market capitalization of 9,7 Md €. The trailing P/E ratio stands at 48.07x, with a forward P/E of 17.18x. The 52-week range spans from 70,80 € to 103,13 €; the current price is 15.5% below the yearly high. Year-over-year revenue growth stands at +7.0%. The net profit margin stands at 8.26%.

💰 Dividende

Revvity, Inc. pays an annual dividend of 0,24 € per share, representing a yield of 0.28%. The payout ratio stands at 13.46%.

📊 Avis des analystes

14 analystes évaluent Revvity, Inc. (RVTY) au consensus : None. L'objectif de cours moyen est de 99,07 €, soit un potentiel de +13.66% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 78,46 € à 126,41 €.

Revvity, Inc. : la thèse d'investissement en détail

Revvity, Inc. (RVTY) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario baissier

Short interest sits at 11.75% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valorisation en contexte

With a PEG ratio of 0.62, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The forward P/E of 17.18x is meaningfully below the trailing 48.07x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to market-like volatility, elevated short interest (11.75%).

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Revvity, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.